Detail akcie Amarin Depository Receipt online

Business Summary: Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Amarin Corporation plc (ADR) revenues decreased 17% to $306.9M. Net loss decreased 44% to $59.1M. Revenues reflect SubTotal decrease of 22% to $285.3M. Lower net loss reflects Selling/General/Admin. Expense decrease of 34% to $187.4M (expense), Stock based compensation expense decrease of 44% to $12.5M (expense), Interest income increase from $2.8M to $11.9M (income).